NAS:MLND (USA) Also trade in: Germany

Millendo Therapeutics Inc

$ 10.51 -0.14 (-1.31%)
Volume: 29,937 Avg Vol (1m): 56,194
Market Cap $: 140.68 Mil Enterprise Value $: 76.38 Mil
P/E (TTM): 0.00 P/B: 2.31
Earnings Power Value -16.64
Net Current Asset Value 4.49
Tangible Book 4.61
Projected FCF -22.4
Median P/S Value 21.45
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 8.2/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 129.82
Cash-To-Debt range over the past 10 years
Min: 22.74, Med: 10000, Max: 10000
Current: 129.82
22.74
10000
Equity-to-Asset 0.84
Equity-to-Asset range over the past 10 years
Min: -6.6, Med: 0.91, Max: 0.96
Current: 0.84
-6.6
0.96
Debt-to-Equity 0.01
Debt-to-Equity range over the past 10 years
Min: -0.01, Med: 0.01, Max: 0.01
Current: 0.01
-0.01
0.01
Debt-to-EBITDA -0.02
Debt-to-EBITDA range over the past 10 years
Min: -0.04, Med: -0.03, Max: -0.02
Current: -0.02
-0.04
-0.02
Piotroski F-Score 3
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 5.17
DISTRESS
GREY
SAFE
Beneish M-Score 99999999.99
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 0%
WACC 8.12%

Profitability & Growth : 3/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
ROE % -52.98
ROE range over the past 10 years
Min: -102.08, Med: -80.38, Max: -52.98
Current: -52.98
-102.08
-52.98
ROA % -46.28
ROA range over the past 10 years
Min: -118.83, Med: -72.25, Max: -46.28
Current: -46.28
-118.83
-46.28
ROC (Joel Greenblatt) % -4445.88
ROC (Joel Greenblatt) range over the past 10 years
Min: -4445.88, Med: -1745.06, Max: -735.18
Current: -4445.88
-4445.88
-735.18
3-Year Total Revenue Growth Rate -100.00
3-Year Revenue Growth Rate range over the past 10 years
Min: 0, Med: 0, Max: -100
Current: -100
0
-100
3-Year Total EBITDA Growth Rate 27.60
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: -8.5, Max: 23.8
Current: 23.8
0
23.8
3-Year EPS w/o NRI Growth Rate 24.30
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: -12.5, Max: 24.3
Current: 24.3
0
24.3

» MLND's 30-Y Financials

Financials (Next Earnings Date: 2019-08-09)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:MLND

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare XPAR:POXEL NAS:EIGR XTAE:CGEN TSXV:EBM NAS:AFMD ROCO:6617 NAS:SPRO XPAR:TNG XBRU:ACPH NAS:AXGT XKRX:203690 NAS:NTEC NAS:ADMA NAS:GMDA NAS:ARDX ROCO:6586 OSTO:IBT B NAS:OSMT SZSE:002680 NAS:AGLE
Traded in other countries 3OS1.Germany
Address 301 North Main Street, Suite 100, Ann Arbor, MI, USA, 48104
OvaScience Inc is a biotechnology company focused on discovering, developing, and commercializing new fertility treatment options for women. The company's patented technology is based on a new fertility treatment option, "the newly discovered Egg precursor cells." Augment, the first treatment, is designed to improve egg health: Energy-producing mitochondria from a patient's own EggPC cells are added to the patient's mature eggs. The OvaPrime treatment is a fertility treatment that could allow a woman to increase her own egg reserve. The OvaTure treatment is a potential next-generation fertility treatment that could allow a woman produce healthy, young, fertilizable eggs without hormone injections.

Ratios

Current vs industry vs history
PB Ratio 2.31
PB Ratio range over the past 10 years
Min: 0.46, Med: 1.37, Max: 7.5
Current: 2.31
0.46
7.5
PS Ratio 250.22
PS Ratio range over the past 10 years
Min: 68.18, Med: 510.78, Max: 99999999.99
Current: 250.22
68.18
99999999.99
EV-to-EBIT -2.52
EV-to-EBIT range over the past 10 years
Min: -18.9, Med: -0.8, Max: 8.8
Current: -2.52
-18.9
8.8
EV-to-EBITDA -2.55
EV-to-EBITDA range over the past 10 years
Min: -19.1, Med: -0.8, Max: 11.8
Current: -2.55
-19.1
11.8
Current Ratio 7.83
Current Ratio range over the past 10 years
Min: 4.82, Med: 11.73, Max: 30.5
Current: 7.83
4.82
30.5
Quick Ratio 7.83
Quick Ratio range over the past 10 years
Min: 4.82, Med: 11.73, Max: 30.5
Current: 7.83
4.82
30.5
Days Payable 4.00
Days Payable range over the past 10 years
Min: 4, Med: 544.01, Max: 599.71
Current: 4
4
599.71

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate 5.30
3-Year Share Buyback Rate range over the past 10 years
Min: -29.4, Med: -13.9, Max: 0
Current: 5.3
-29.4
0

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 2.28
Price-to-Tangible-Book range over the past 10 years
Min: 0.5, Med: 2.38, Max: 19.3
Current: 2.28
0.5
19.3
Price-to-Median-PS-Value 0.49
Price-to-Median-PS-Value range over the past 10 years
Min: 0.14, Med: 0.65, Max: 126.14
Current: 0.49
0.14
126.14
Earnings Yield (Joel Greenblatt) % -40.14
Earnings Yield (Greenblatt) range over the past 10 years
Min: -10369.2, Med: -11.05, Max: 9537.4
Current: -40.14
-10369.2
9537.4

More Statistics

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 3
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy N